

MD Anderson Ovarian SPORE publications – 2009

1. Agarwal R, Jurisica I, Mills GB, Cheng KW. **The emerging role of the RAB25 small GTPase in cancer.** *Traffic* 10(11):1561-8, 2009. PMID: 19719478; PMCID: PMC3258497.
2. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC Jr, Kruk PA. **Urinary levels of Bcl-2 are elevated in ovarian cancer patients.** *Gynecol Oncol* 112(1):60-7, 2009. PMID: 19007973; PMCID: PMC3729448.
3. Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK. **Neuroendocrine modulation of cancer progression.** *Brain Behav Immun* 23(1):10-5, 2009. PMID: 18638541; PMCID: PMC2630522.
4. Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK. **Estrous cycle modulates ovarian carcinoma growth.** *Clin Cancer Res* 15(9):2971-8, 2009. PMID: 19383821; PMCID: PMC2743312.
5. Bast RC Jr, Hennessy B, Mills GB. **The biology of ovarian cancer: new opportunities for translation.** *Nat Rev Cancer* 9(6):415-28, 2009. PMID: 19461667; PMCID: PMC2814299.
6. Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. **Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?** *Gynecol Oncol* 113(1):86-90, 2009. PMID: 19162310.
7. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J. **ALDH1 expression correlates with favorable prognosis in ovarian cancers.** *Mod Pathol* 22(6):817-23, 2009. PMID: 19329942; PMCID: PMC2692456.
8. Chang B, Liu G, Yang G, Mercado-Uribe I, Huang M, Liu J. **REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells.** *Cell Cycle* 8(5):780-6, 2009. PMID: 19221489.
9. Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, Bast RC, Behringer RR. **CA125/MUC16 is dispensable for mouse development and reproduction.** *PLoS One* 4(3):e4675, 2009. PMID: 19262696; PMCID: PMC2650410.
10. Daniels MS, Urbauer DL, Stanley JL, Johnson KG, Lu KH. **Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer.** *Genet Med* 11(9):624-8, 2009. PMID: 19606053.
11. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. **Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.** *Gynecol Oncol* 114(1):48-52, 2009. PMID: 19361839.
12. Guo W, Wu S, Wang L, Wang RY, Wei X, Liu J, Fang B. **Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1).** *Mol Cancer Ther* 8(2):441-8, 2009. PMID: 19208825; PMCID: PMC2653085.
13. Han CH, Wei Q, Lu KK, Liu Z, Mills GB, Wang LE. **Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer.** *Int J Clin Exp Med* 2(4):289-99, 2009. PMID: 20057973; PMCID: PMC2802047.
14. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, Fishman DA. **LPA receptor 2 mediates LPA-induced endometrial cancer invasion.** *Gynecol Oncol* 112(1):215-23, 2009. PMID: 19019417.
15. Hung MC, Mills GB, Yu D. **Oxygen sensor boosts growth factor signaling.** *Nat Med* 15(3):246-7, 2009. PMID: 19265822.
16. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. **Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the**

inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69(1):143-50, 2009. PMID: 19117997; PMCID: PMC2613546.

17. Jeong JW, Lee HS, Franco HL, Broaddus RR, Taketo MM, Tsai SY, Lydon JP, DeMayo FJ. **beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus.** Oncogene 28(1):31-40, 2009. PMID: 18806829; PMCID: PMC2646831.
18. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK. **EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.** Cancer 115(12):2684-92, 2009. PMID: 19396818; PMCID: PMC3139331.
19. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M, Marini FC. **Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging.** Stem Cells 27(10):2614-23, 2009. PMID: 19650040.
20. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. **Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.** Cancer Biol Ther 8(23):2263-72, 2009. PMID: 19829059; PMCID: PMC3400500.
21. Ko SY, Guo H, Barengo N, Naora H. **Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E.** Clin Cancer Res 15(13):4336-47, 2009. PMID: 19458052.
22. Kuo HP, Lee DF, Xia W, Lai CC, Li LY, Hung MC. **Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation.** Biochem Biophys Res Commun 389(1):156-61, 2009. PMID: 19716809; PMCID: PMC2753275.
23. Kuo HP, Lee DF, Xia W, Wei Y, Hung MC. **TNFalpha induces HIF-1alpha expression through activation of IKKbeta.** Biochem Biophys Res Commun 389(4):640-4, 2009. PMID: 19766100; PMCID: PMC2762003.
24. Kurzrock R, Pilat S, Bartolazzi M, Sanders D, Van Wart Hood J, Tucker SD, Webster K, Mallamaci MA, Strand S, Babcock E, Bast RC Jr. **Project Zero Delay: a process for accelerating the activation of cancer clinical trials.** J Clin Oncol 27(26):4433-40, 2009. PMID: 19652061.
25. Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. **Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells.** Neoplasia 11(6):529-41, 2009. PMID: 19484142; PMCID: PMC2685442.
26. Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK. **Glucose as a prognostic factor in ovarian carcinoma.** Cancer 115(5):1021-7, 2009. PMID: 19156916; PMCID: PMC2649990.
27. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, Shen J, Chen CT, Huo L, Hsu MC, Li CW, Ding Q, Liao TL, Lai CC, Lin AC, Chang YH, Tsai SF, Li LY, Hung MC. **KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta.** Mol Cell 36(1):131-40, 2009. PMID: 19818716; PMCID: PMC2770835.
28. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. **EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.** J Natl Cancer Inst 101(17):1193-205, 2009. PMID: 19641174; PMCID: PMC2736292.

29. Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. **Surgical stress promotes tumor growth in ovarian carcinoma.** Clin Cancer Res 15(8):2695-702, 2009. PMID: 19351748; PMCID: PMC2746852.
30. Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE. **Role of eotaxin-1 signaling in ovarian cancer.** Clin Cancer Res 15(8):2647-56, 2009. PMID: 19351767; PMCID: PMC2669845.
31. Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. **Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis.** Am J Obstet Gynecol 200(2):177.e1-9, 2009. PMID: 19110234.
32. Liao Y, Wei Y, Zhou X, Yang JY, Dai C, Chen YJ, Agarwal NK, Sarbassov D, Shi D, Yu D, Hung MC. **Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation.** Oncogene 28(26):2436-45, 2009. PMID: 19448664; PMCID: PMC2748248.
33. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB. **Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.** Cancer Cell 15(6):539-50, 2009. PMID: 19477432.
34. Lu Z, Bast RC Jr. **Tumor suppressor genes.** Cancer Treat Res 149:109-29, 2009. PMID: 19763433.
35. Lutgendorf SK, DeGeest K, Sung CY, Arevalo JM, Penedo F, Lucci J, 3rd, Goodheart M, Lubaroff D, Farley DM, Sood AK, Cole SW. **Depression, social support, and beta-adrenergic transcription control in human ovarian cancer.** Brain Behav Immun 23(2):176-83, 2009. PMID: 18550328; PMCID: PMC2677379.
36. Mangala LS, Han HD, Lopez-Berestein G, Sood AK. **Liposomal siRNA for ovarian cancer.** Methods Mol Biol 555:29-42, 2009. PMID: 19495686.
37. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. **Therapeutic Targeting of ATP7B in Ovarian Carcinoma.** Clin Cancer Res 15(11):3770-80, 2009. PMID: 19470734; PMCID: PMC2752981.
38. Matei D, Miller AM, Monahan P, Gershenson D, Zhao Q, Cella D, Champion VL, Williams SD. **Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study.** J Clin Oncol 27(25):4142-9, 2009. PMID: 19636015; PMCID: PMC2734426.
39. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, Chang JT, Kuo WL, Gusberg AH, Whitaker RS, Gray JW, Fujii S, Berchuck A, Murphy SK. **Yin yang 1 modulates taxane response in epithelial ovarian cancer.** Mol Cancer Res 7(2):210-20, 2009. PMID: 19208743; PMCID: PMC2675878.
40. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. **Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).** Lancet Oncol 10(4):327-40, 2009. PMID: 19282241.

41. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. **Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.** *Cancer Biol Ther* 8(16):1596-603, 2009. PMID: 19738426; PMCID: PMC3916970.
42. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ. **A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.** *Gynecol Oncol* 112(1):40-6, 2009. PMID: 18851871; PMCID: PMC3594094.
43. Moroney JW, Sood AK, Coleman RL. **Aflibercept in epithelial ovarian carcinoma.** *Future Oncol* 5(5):591-600, 2009. PMID: 19519199; PMCID: PMC2744352.
44. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Borresen-Dale AL, Mills GB. **Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.** *PLoS One* 4(5):e5583, 2009. PMID: 19440550; PMCID: PMC2679144.
45. Neeley ES, Kornblau SM, Coombes KR, Baggerly KA. **Variable slope normalization of reverse phase protein arrays.** *Bioinformatics* 25(11):1384-9, 2009. PMID: 19336447; PMCID: PMC3968550.
46. Rampurwala M, Ravoori MK, Wei W, Johnson VE, Vikram R, Kundra V. **Visualization and quantification of intraperitoneal tumors by in vivo computed tomography using negative contrast enhancement strategy in a mouse model of ovarian cancer.** *Transl Oncol* 2(2):96-106, 2009. PMID: 19412425; PMCID: PMC2670577.
47. Rohozinski J, Anderson ML, Broaddus RE, Edwards CL, Bishop CE. **Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers.** *PLoS One* 4(3):e5064, 2009. PMID: 19333399; PMCID: PMC2660244.
48. Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, Zheng J, Xue FX, Liu J. **Ovarian cancer: pathology, biology, and disease models.** *Front Biosci (Landmark Ed)* 14:2089-102, 2009. PMID: 19273186; PMCID: PMC2858969.
49. Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC Jr, Liao WS. **MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.** *Cancer* 115(17):3897-908, 2009. PMID: 19517469; PMCID: PMC3061353.
50. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS. **A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.** *Gynecol Oncol* 113(2):210-5, 2009. PMID: 19264351.
51. Shahzad MM, Lopez-Berestein G, Sood AK. **Novel strategies for reversing platinum resistance.** *Drug Resist Updat* 12(6):148-52, 2009. PMID: 19805003; PMCID: PMC2789192.
52. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. **Dual targeting of EphA2 and FAK in ovarian carcinoma.** *Cancer Biol Ther* 8(11):1027-34, 2009. PMID: 19395869; PMCID: PMC2748749.
53. Shan W, Liu J. **Epithelial ovarian cancer: focus on genetics and animal models.** *Cell Cycle* 8(5):731-5, 2009. PMID: 19221485.
54. Shinn EH, Taylor CL, Kilgore K, Valentine A, Bodurka DC, Kavanagh J, Sood A, Li Y, Basen-Engquist K. **Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients.** *Palliat Support Care* 7(3):299-306, 2009. PMID: 19788771; PMCID: PMC3265166.

55. Song J, Shih le M, Chan DW, Zhang Z. **Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.** *Neoplasia* 11(6):605-14, 1 p following 14, 2009. PMID: 19484149; PMCID: PMC2685449.
56. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. **Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism.** *Clin Cancer Res* 15(2):492-501, 2009. PMID: 19147754.
57. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. **Functional significance of VEGFR-2 on ovarian cancer cells.** *Int J Cancer* 124(5):1045-53, 2009. PMID: 19058181; PMCID: PMC2668132.
58. Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK. **Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.** *Gynecol Oncol* 114(2):219-24, 2009. PMID: 19446868.
59. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. **Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.** *Gynecol Oncol* 114(3):431-6, 2009. PMID: 19524286.
60. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. **PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.** *Mod Pathol* 22(9):1243-50, 2009. PMID: 19525924; PMCID: PMC2736318.
61. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. **AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.** *Cancer Cell* 16(1):21-32, 2009. PMID: 19573809; PMCID: PMC2752826.
62. Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S. **Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.** *Eur J Cancer* 45(13):2324-32, 2009. PMID: 19515553.
63. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL, Huo LF, Miller S, Hung MC. **Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer.** *Mol Carcinog* 48(7):610-7, 2009. PMID: 19058255; PMCID: PMC2718429.
64. Xiao X, Bai P, Bui Nguyen TM, Xiao J, Liu S, Yang G, Hu L, Chen X, Zhang X, Liu J, Wang H. **The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway.** *Mol Cancer Ther* 8(5):1179-88, 2009. PMID: 19435869.
65. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC Jr, Hung MC. **A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.** *Mol Cancer Ther* 8(8):2375-82, 2009. PMID: 19671744; PMCID: PMC2759534.
66. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. **Rak functions as a tumor suppressor by regulating PTEN protein stability and function.** *Cancer Cell* 15(4):304-14, 2009. PMID: 19345329; PMCID: PMC2673492.
67. Zheng H, Hu W, Deavers MT, Shen DY, Fu S, Li YF, Kavanagh JJ. **Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer.**

Am J Obstet Gynecol 201(4):367.e1-6, 2009. PMID: 19608149.